Line Marchand

No ORCID on file · 2 papers in corpus

rct 2020

Effects of combined GnRH receptor antagonist linzagolix and hormonal add-back therapy on vaginal bleeding-delayed add-back onset does not improve bleeding pattern

Reproductive sciences (Thousand Oaks, Calif.) ·doi:10.1007/s43032-020-00172-z

Linzagolix is a novel, oral GnRH receptor antagonist developed for the treatment of endometriosis and uterine fibroids. We assessed high-dose linzagolix safety and bleeding pattern effects in healthy women using combined versus delayed horm…

rct 2017

Gonadotropin-Releasing Hormone Receptor Antagonist Mono- and Combination Therapy With Estradiol/Norethindrone Acetate Add-Back: Pharmacodynamics and Safety of OBE2109

The Journal of clinical endocrinology and metabolism ·doi:10.1210/jc.2017-01875

CONTEXT: OBE2109 is a potent, oral gonadotropin-releasing hormone receptor antagonist being developed for the treatment of sex-hormone-dependent diseases in women. OBJECTIVE: We assessed the pharmacodynamics and safety of OBE2109 alone and…